Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
i3.1 Probiotic in ME/CFS
NCT06211062Phase 2Recruiting
- Sponsor
- Nova Southeastern University
- Start
- Dec 2022
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial (4 arms), sponsored by Nova Southeastern University. Primary endpoints: Incidence of Intervention-Related Adverse Events at 8 weeks, Measurement of Biomarker Response to an Intervention in the Blood at 8 weeks and 3 more. Started Dec 2022; status: recruiting.
Beyond the preview
Go deeper on NCT06211062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211062.